HALOZYME THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$3
Book Value Per Share
$0
Free Cash Flow Per Share
$5
Cash Per Share
$1
Revenue Per Share
$11
OCF Per Share
$5
Return on Equity
153.6%
Return on Assets
13.8%
Return on Invested Capital
15.7%
Debt to Equity
43.89
Current Ratio
4.66
Quick Ratio
3.66
Asset Turnover
0.61
Days Sales Outstanding
111.41
Days Payables Outstanding
33.34
Days Inventory On Hand
281.56
Cash Conversion Cycle
359.62
R&D / Revenue
5.8%
SBC / Revenue
3.7%
Capex / Revenue
0.5%
Working Capital
$648M
Net Current Asset Value
$-1.65B
Invested Capital
$2.19B
OCF / Net Income
2.06
FCF / Net Income
2.03
Accruals Ratio (Sloan)
-13.3%
Net Debt
$2.01B
Net Debt / EBITDA
4.18
Interest Coverage
25.87
Cash Coverage
35.95
Capex Coverage
93.48
Tangible Common Equity
$-1.51B
TCE / Total Assets
-59.9%
Goodwill / Total Assets
23.0%
NOPAT
$318M
Cash ROIC
31.7%
WC / Revenue
46.4%
Capex / D&A
0.61
Reinvestment Rate
153.8%
Total Payout Ratio
108.0%
Asset Growth vs Revenue Growth
-15.2%
Revenue 5Y CAGR
39.2%
EPS 5Y CAGR
19.7%
FCF 5Y CAGR
64.8%
EBITDA 5Y CAGR
26.6%
Book Value 5Y CAGR
-20.2%
Stock Price (FY-end)
$67
Market Cap
$8.34B
P/E Ratio
26.31
P/S Ratio
5.97
P/B Ratio
170.83
P/TB Ratio
—
P/OCF Ratio
12.80
P/FCF Ratio
12.94
Enterprise Value
$10.35B
EV / EBITDA
21.54
EV / Sales
7.41
EV / FCF
16.05
FCF Yield
7.7%
Shareholder Yield
3.5%
Buyback Yield
4.1%
R&D Yield
1.0%
Capex Yield
0.1%
Operating Leverage
-0.40
Graham Number
$5
Shares Variation (YoY)
-4.3%
Beta (5Y)
0.84
Cost of Equity
8.7%
Cost of Debt (after tax)
0.6%
WACC
7.0%
ROIC - WACC Spread
8.7%
52W High
$78
52W Low
$48
Trailing Return 1Y
39.8%
Trailing Return 5Y
57.8%
F-Score (Piotroski)
5.00
M-Score (Beneish)
-2.52
Z-Score (Altman)
3.52
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.